LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $4.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $5K to $75K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $4.1M and bought $0 of AMGN stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Miller, Derek (SVP, Human Resources), who sold $1.6M. The latest filing was on Aug 13, 2026.
Rep. David J. Taylor (R) bought $1K to $15K on Sep 22, 2026, disclosed 9 days later. Rep. David J. Taylor (R) sold $1K to $15K on Aug 26, 2026, disclosed 10 days later. Rep. David J. Taylor (R) sold $1K to $15K on Aug 26, 2026, disclosed 10 days later. Sen. Sheldon Whitehouse (D) sold $1K to $15K on Aug 12, 2026, disclosed 21 days later. In total, 2 members disclosed 5 AMGN trades with trade dates in the last 180 days, filed a median 10 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
D.E. Shaw
$404.6M
added
Two Sigma
$383.5M
added
Citadel
$189.8M
added
Buys (1)
Sells (2)
No tracked top-trader positions in AMGN right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Financial period
Q2 2026
Adjusted EPS
$5.62 expected
Revenue
No comparable estimate
FY2026 guidance
$38.20B to $39.40B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $6.29 / $5.62Yahoo Finance | +11.97% beat | $10.05B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $5.15 / $4.77Yahoo Finance | +8.04% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 3, 2026 | $5.29 / $4.73Yahoo Finance | +11.94% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $5.64 / $5.01Yahoo Finance | +12.47% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | $6.02 / $5.28Alpha Vantage | +14.02% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $4.90 / $4.26Alpha Vantage | +15.02% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 4, 2025 | $5.31 / $5.08Alpha Vantage | +4.53% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $5.58 / $5.11Alpha Vantage | +9.20% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$5.47 to $6.07
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $9.56B | $9.90B | $8.62B | $10.05B |
| Cost of what it sold | $3.08B | $1.79B | $2.74B | $2.81B |
| Gross profit | $6.47B | $8.11B | $5.87B | $7.24B |
| What it spent | ||||
| Research and development | $1.90B | $2.15B | $1.72B | $1.87B |
| Sales and admin | $1.72B | $1.95B | $1.60B | $1.75B |
| Other operating costs | $329.0M | $61.0M | -$113.0M | $116.0M |
| Total operating expenses | $3.95B | $4.16B | $3.21B | $3.73B |
| What was left | ||||
| Operating profit | $2.53B | $3.94B | $2.67B | $3.51B |
| Interest on debt | $685.0M | $653.0M | $657.0M | $673.0M |
| Profit before tax | $3.92B | $1.51B | $2.08B | $2.77B |
| Tax | $705.0M | $181.0M | $265.0M | $393.0M |
| Net profit | $3.22B | $1.33B | $1.82B | $2.38B |
| EBITDA | $5.91B | $3.30B | $3.86B | $4.55B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
What Amgen (AMGN)'s Tezspire Trial Win Means For Shareholders
BullishOct 15HBW Advisory Services LLC Purchases 2,611 Shares of Amgen Inc. $AMGN
Leans bullishOct 15Perpetual Ltd Sells 1,598 Shares of Regeneron Pharmaceuticals, Inc. $REGN
NeutralOct 15Form DEF 14A Amgen Inc For: 15 October By Investing.com
NeutralOct 15Sanders Morris Harris LLC Makes New Investment in Amgen Inc. $AMGN
Leans bullishOct 15Boeing's Secret Weapon Isn't on the Factory Floor -- It's in the Boardroom
NeutralOct 15Boeing's Secret Weapon Isn't on the Factory Floor -- It's in the Boardroom
NeutralOct 15How Phase 2 Lupus Data At Biogen (BIIB) Has Changed Its Investment Story
NeutralOct 1430 macro signals shaping AMGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results